Aspirin Cuts Dementia Risk 70% in Genetic Group

A genetic test could someday help identify who might benefit from aspirin to prevent dementia, according to groundbreaking research from Monash University.

Researchers analyzed genetic data from more than 13,500 older adults and found something remarkable. Among people with a particular genetic trait related to platelet count, only 1% of those taking low-dose aspirin developed dementia compared to 3.3% taking a placebo.

That translates to about 23 fewer dementia cases per 1,000 people in this genetic group. The finding could transform how we approach dementia prevention in a world where 446,500 Australians currently live with the condition.

Dr. Peter Fransquet, the lead researcher, explains why this matters. Previous studies showed aspirin didn't prevent dementia when testing everyone together, but genetics may reveal who actually benefits from the treatment.

The genetic profile involves platelet count, which relates to the blood cells that help with clotting. Scientists have long suspected platelets play a role in dementia, and this research points them toward a promising new investigation path.

The discovery isn't linked to established Alzheimer's genes. Instead, it opens an entirely new avenue for understanding how dementia develops and how we might stop it.

The Bright Side

This research represents a shift toward personalized medicine that could make dementia prevention accessible to millions. Aspirin is already cheap, widely available, and familiar to doctors and patients alike.

With over one million Australians projected to have dementia by 2065, identifying who can benefit from simple preventive treatments becomes crucial. A genetic test could help people make informed decisions with their doctors about prevention strategies.

The next step involves confirming these findings in new studies and designing trials specifically for people with this genetic profile. Researchers want to ensure the benefits outweigh the risks before recommending any treatment changes.

There is an important caveat. The same genetic group taking aspirin experienced more serious bleeding events, about 23 additional cases per 1,000 people. That's why researchers stress this isn't ready for clinical use yet.

Fransquet is clear about the path forward. People shouldn't start taking aspirin based solely on this study without consulting their doctor, but the research gives scientists a concrete direction for developing targeted prevention strategies.

The possibility of matching the right treatment to the right person based on their unique biology brings hope to dementia research.